Navigation Links
YM BIOSCIENCES REPORTS NIMOTUZUMAB NSCLC CLINICAL DATA AT ASCO ANNUAL MEETING
Date:6/2/2008

MISSISSAUGA, June 2 /PRNewswire-FirstCall/ - YM BioSciences Inc. (AMEX: YMI, TSX: YM, AIM: YMBA), an oncology company that identifies, develops and commercializes differentiated products for patients worldwide, today announced that updated preliminary trial results, including survival, response rate and overall safety data, from its escalating dose trial of nimotuzumab were presented in a poster presentation on June 1st, 2008 at the Annual Meeting of the American Society of Clinical Oncology (ASCO). The phase I trial is evaluating nimotuzumab, a humanized monoclonal antibody that targets the epidermal growth factor receptor, in combination with external radiotherapy in palliative treatment of patients diagnosed with stage IIb, III or IV non-small cell lung cancer (NSCLC) ineligible for chemotherapy-containing regimens.

"The median survival of 60 weeks in the palliative setting reported in this trial compares favorably with other recent trials in the same scenario, and suggests that the combination of nimotuzumab with radiation has the potential to provide a survival advantage to patients over radiation alone in the curative setting, the only alternative available to patients who are ineligible for, or unable to tolerate, chemotherapy-containing regimens," said David Allan, Chairman and CEO of YM BioSciences. "There is a significant subset of patients whose overall condition does not permit administration of chemotherapy in a combined-modality treatment to enhance their curative prospects."

Substantial radiological responses and meaningful clinical responses were seen in patients treated with the combination of nimotuzumab and radiation in each dosing cohort. This included an 89% Disease Control Rate of which 50% were Partial Responses. Eleven of the 18 patients were Stage IV, five were stage IIIb and two were Stage IIIa. No Stage II patients were enrolled. Patients were treated for eight weeks and then every two weeks until progression. Continue
'/>"/>

SOURCE YM BioSciences Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
2. Selection of Development Candidate Triggers $0.5 Million Milestone Payment to Ardea Biosciences, Inc.
3. ImmuneRegen BioSciences Files 8-K that Highlights Enclosed Shareholder Letter Discussing Recent Achievements and Outlook
4. ONCOSCIENCE AG, THE EUROPEAN PARTNER OF YM BIOSCIENCES, ANNOUNCES COMPLETION OF PATIENT ENROLLMENT IN PHASE III BRAIN CANCER TRIAL OF NIMOTUZUMAB
5. Pressure BioSciences, Inc. Reports Second Quarter 2007 Financial Results and Provides Business Update
6. YM BIOSCIENCES, EUROPEAN PARTNER, ONCOSCIENCE AG, ANNOUNCES INITIATION OF ADVANCED NIMOTUZUMAB TRIALS IN ADULT GLIOMA AND PANCREATIC CANCER
7. Monogram Biosciences to Present at the Thomas Weisel Partners Healthcare Conference 2007
8. Magellan Biosciences Names Steven E. Diamond, PhD, Chief Scientific Officer
9. Pressure BioSciences, Inc. Issued First Patent in Canada
10. Neurocrine Biosciences to Present at the BioCentury: Newsmakers in the Biotech Industry Conference
11. YM BioSciences USA cleared by US FDA to initiate Phase II clinical trial of nimotuzumab in children with inoperable, recurrent brain cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2015)... Achieved primarily through a proprietary paraffin and stain ... 100x better detail than the industry standard. But ... microscopy methods, it needed another medium to measure its ... of reference because it represents the highest standard of ... earliest discovery days of Ultralight Histology was to reverse ...
(Date:5/4/2015)... 2015 - New Massive Open ... prepare for the United States Medical Licensing Examination ... technical and medical information products and services, announced today ... Online Course) designed to help medical students prepare for ... the first and most daunting of the three exams ...
(Date:5/4/2015)... ALISO VIEJO, Calif. , May 4, 2015 /PRNewswire/ ... to eliminate preventable hospitalizations, has teamed with the ... effect of Sentrian technology on 1,000 patients with chronic ... nearly 13 million Americans and is the nation,s third ... plan members of CareMore Health System , a ...
(Date:5/1/2015)... OncoTAb, Inc., a University of ... that Pinku Mukherjee, Ph.D. has received the O. ... highest faculty honor. Mukherjee received the award, which recognizes ... innovative research and development of cancer diagnostics and treatments. ... moment in my scientific career,” said Mukherjee, OncoTAb Co-founder ...
Breaking Biology Technology:Elsevier's Free MOOC Prepares Med Students for Licensing Exam 2Elsevier's Free MOOC Prepares Med Students for Licensing Exam 3CareMore, Scripps Translational Science Institute, and Sentrian Launch Landmark Study of Remote Patient Monitoring for COPD Population 2CareMore, Scripps Translational Science Institute, and Sentrian Launch Landmark Study of Remote Patient Monitoring for COPD Population 3CareMore, Scripps Translational Science Institute, and Sentrian Launch Landmark Study of Remote Patient Monitoring for COPD Population 4CareMore, Scripps Translational Science Institute, and Sentrian Launch Landmark Study of Remote Patient Monitoring for COPD Population 5OncoTAb CSO Awarded the University of North Carolina’s O. Max Gardner Award 2
... LUND, Sweden, January 18 ,ThromboGenics NV (Euronext ... (Nordic Exchange: BINV) announce today that they,have ... Denmark to,initiate a Phase I clinical trial ... a monoclonal antibody that targets the angiogenic ...
... Calif. University of California, Irvine researchers have identified ... cerebral cortex, a finding that could lead to stem ... as stroke and Alzheimers. , Dr. Edwin Monuki, doctoral ... of Pathology & Laboratory Medicine and Developmental & Cell ...
... last 12 ... months, ... the global leader in,pharmaceutical services will open an office in Wilmington, N.C. ... development., The new Wilmington office is Quintiles, second expansion within the,state ...
Cached Biology Technology:ThromboGenics and BioInvent Receive Approval to Begin Clinical Trials of TB-403 for the Treatment of Cancer 2ThromboGenics and BioInvent Receive Approval to Begin Clinical Trials of TB-403 for the Treatment of Cancer 3ThromboGenics and BioInvent Receive Approval to Begin Clinical Trials of TB-403 for the Treatment of Cancer 4ThromboGenics and BioInvent Receive Approval to Begin Clinical Trials of TB-403 for the Treatment of Cancer 5Discovery of 'creator' gene for cerebral cortex points to potential stem cell treatments 2Quintiles to Open Clinical Research Office in Wilmington, NC 2
(Date:3/24/2015)... DUBLIN , Mar. 24, 2015 Research and ... addition of the "Global Iris Recognition Market 2015-2019" ... forecast the Global Iris Recognition market to grow at ... This report covers the present scenario and ... for the period 2015-2019. To calculate the market size, ...
(Date:3/24/2015)... BEACH GARDENS, Fla. , March 24, 2015 ... biometric identity management solutions, today announced that its ... premium clothing accessory retailer Goorin Bros . ... The Crossmatch biometrics-based solution secures access to the ... from the increased risk of data breaches. ...
(Date:3/23/2015)... -- In the 2014 fiscal year, irs.gov recorded over $100 ... accounts for a fraction of the estimated losses for ... $11 billion globally. The polygraph has traditionally been used ... Investor Mark Saint Juste along with former ... partnered to administer the test in a new way: ...
Breaking Biology News(10 mins):Global Iris Recognition Market 2015-2019 with 3M Cogent, Bioenable Technologies, Cross Match Technology, Iris ID Systems & Safran Dominating 2Crossmatch Fingerprint Readers Help Retailer Prevent Data Breaches at Point-of-Sale 2Polygraph Test Now Used to Protect Investors From Fraud 2Polygraph Test Now Used to Protect Investors From Fraud 3
... that a fundamental building block in the cells ... on a separate branch of the evolutionary tree--in ... at least 420 million years ago. ... the group that includes conifers, ginkgos and related ...
... Geneticists of Leiden University Medical Centre (LUMC) are the ... She is also the first European whose DNA sequence ... researchers this morning, during a special press conference at ... in the Netherlands. Following in-depth analysis, ...
... of the Watson School of Biological Sciences, has been ... Dr. Joshua-Tor, a structural biologist whose work ... new HHMI Investigators selected from among 1,070 applicants. They ... who lead Hughes laboratories at 64 institutions. At ...
Cached Biology News:When plants 'think' alike 2Leiden scientists sequence first female DNA 2Leemor Joshua-Tor, PhD, CSHL biologist and WSBS dean, is named an HHMI Investigator 2Leemor Joshua-Tor, PhD, CSHL biologist and WSBS dean, is named an HHMI Investigator 3
Rabbit anti Xanthine Oxidase Xanthine Oxidase, Bovine Buttermilk...
... system uses three Adept CE 4100 high ... flow rate in one microlitre increaments. ... detector, provides added flexibility. The ... photodiode array detection and provides superior stability ...
... range has now been expanded ... quaternary low pressure mixing pump ... mixing pump. These space ... even more versatility to modular ...
...
Biology Products: